Observational assessment of treatment outcomes for patients with primary brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the treatment and outcomes of patients diagnosed with rare primary brain tumors using the new 2021 WHO classification and cIMPACT-NOW recommendations. It seeks to determine if the updated classification leads to more consistent patient groupings compared to the previous 2016 classification. By collecting data on treatment experiences and outcomes, the study will help establish provisional guidelines for managing these newly defined tumor entities. The focus is on newly diagnosed or recurrent tumors, with an emphasis on those considered rare.

Why it matters

Who can join: the full rules

* Age ≥ legal age of consent
* Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest
* Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16.
* Available MRI/CT scans from primary brain tumour at initial diagnosis
* Patient's consent

Deceased patient:

The clinical data and/or biological material and/or CT/MRI/PET images can be accessed and used if at least one of the following three conditions is met:

* The patient agreed beforehand in his/her lifetime to a further use of his/her data and/or biological material and/or CT/MRI/PET images, or,
* There is consent of a relative to use data and/or biological material and/or CT/MRI/PET images of the deceased patient, or,
* There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients).

Additionally, in all cases the following three points need to be fulfilled:

* No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT/MR/PET images for research purposes
* A notification to an ethics committee for the re-use of these data, biological material and CT/MRI/PET images
* Any other national requirements are fulfilled, if applicable

Where it's running

• Innsbruck Universitaetsklinik
  Innsbruck, Austria Recruiting
• Universitaetsklinikum Wien - AKH unikliniken
  Vienna, Austria Recruiting
• Onze Lieve Vrouw Ziekenhuis
  Aalst, Belgium Recruiting
• Institut Jules Bordet
  Anderlecht, Belgium Recruiting
• Universitair Ziekenhuis Brussel
  Brussels, Belgium Recruiting
• C.H.U. Sart-Tilman
  Liège, Belgium Recruiting

Study contacts

• Principal investigator: Michael Weller — EORTC Study Coordinator
• Study coordinator: Eortc Hq
• Email: eortc@eortc.org
• Phone: +32 2 774 1611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating genetic and molecular profiles of pediatric brain tumors in China

  This study is trying to understand the genetic makeup of brain tumors in children to see how it affects their treatment and recovery.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT05672043

• Locoregional immunotherapy using CAR T cells for pediatric brain tumors

  This study is testing a new treatment using specially modified immune cells to see if it can help children and young adults with certain types of brain tumors feel better.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT04185038

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Identifying biomarkers to predict cognitive decline after radiation therapy for brain tumors

  This study is trying to find specific markers in blood and spinal fluid from young patients with brain tumors to see if they can predict problems with thinking and memory after radiation treatment.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT06779487

• Testing PLX038 for brain and spinal cord tumors with MYC or MYCN amplifications

  This study is testing a new treatment called PLX038 for adults with brain and spinal cord tumors that have specific gene changes to see if it helps improve their condition.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06161519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.